MCID: AMP003
MIFTS: 39

Ampulla of Vater Neoplasm

Categories: Cancer diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Ampulla of Vater Neoplasm

MalaCards integrated aliases for Ampulla of Vater Neoplasm:

Name: Ampulla of Vater Neoplasm 12 14
Carcinoma of Ampulla of Vater 12 69
Ampulla of Vater Carcinoma 12 14
Ampullary Carcinoma 12 55
Carcinoma of the Ampulla of Vater 55
Tumor of the Ampulla of Vater 12
Neoplasm of Ampulla of Vater 69
Ampulla of Vater Cancer 12
Ampulloma 55

Characteristics:

Orphanet epidemiological data:

55
carcinoma of the ampulla of vater
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:10022 DOID:4932
NCIt 46 C4443 C3908
SNOMED-CT 64 126858004 254609000
Orphanet 55 ORPHA300557
UMLS via Orphanet 70 C0262401
ICD10 via Orphanet 33 C24.1
ICD10 32 C24.1

Summaries for Ampulla of Vater Neoplasm

Disease Ontology : 12 An ampulla of Vater cancer that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Ampulla of Vater Neoplasm, also known as carcinoma of ampulla of vater, is related to ampulla of vater adenocarcinoma and adenosquamous carcinoma. An important gene associated with Ampulla of Vater Neoplasm is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Gastric cancer and O-linked glycosylation. The drugs Oxaliplatin and Pancrelipase have been mentioned in the context of this disorder. Related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Ampulla of Vater Neoplasm

Diseases related to Ampulla of Vater Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 216)
# Related Disease Score Top Affiliating Genes
1 ampulla of vater adenocarcinoma 30.6 CDX2 KRT17 KRT20 KRT7 MUC1 MUC2
2 adenosquamous carcinoma 30.5 KRAS KRT7 MUC1
3 cholecystitis 30.1 MUC1 MUC2 MUC6
4 neuroendocrine tumor 29.7 KRT20 KRT7 SST
5 adenoma 29.7 KRAS KRT7 MUC2 SST
6 ampulla of vater squamous cell carcinoma 11.2
7 ampulla of vater adenosquamous carcinoma 11.2
8 sigmoid neoplasm 10.5 HRAS KRAS
9 schimmelpenning-feuerstein-mims syndrome 10.5 HRAS KRAS
10 paronychia 10.5 HRAS KRAS
11 bile duct cysts 10.5 HRAS KRAS
12 secondary hypertrophic osteoarthropathy 10.5 HRAS KRAS
13 nevus, epidermal 10.5 HRAS KRAS
14 lung adenoid cystic carcinoma 10.4 HRAS KRAS
15 ovary serous adenocarcinoma 10.4 HRAS KRAS
16 syringocystadenoma papilliferum 10.4 KRAS MUC1
17 mucinous intrahepatic cholangiocarcinoma 10.4 CDX2 MUC2
18 ovarian cystadenocarcinoma 10.4 HRAS KRAS
19 middle ear adenoma 10.4 KRT7 MUC1
20 pulmonic stenosis 10.4 HRAS KRAS
21 endosalpingiosis 10.4 KRT7 MUC1
22 acneiform dermatitis 10.4 HRAS KRAS
23 parachordoma 10.4 KRT7 MUC1
24 malignant mixed mullerian tumor 10.4 KRT7 MUC1
25 nodular hidradenoma 10.4 KRT7 MUC1
26 mucinous adenofibroma 10.4 CDX2 KRT7
27 eccrine porocarcinoma 10.4 KRT7 MUC1
28 apocrine adenocarcinoma 10.4 KRT7 MUC1
29 monophasic synovial sarcoma 10.4 KRT7 MUC1
30 nephrogenic adenoma 10.4 KRT7 MUC1
31 chronic cholangitis 10.4 CDX2 MUC2
32 epithelial predominant wilms' tumor 10.4 CDX2 KRT7
33 hidradenoma 10.3 KRT7 MUC1
34 well-differentiated liposarcoma 10.3 KRT7 MUC1
35 microinvasive gastric cancer 10.3 CDX2 MUC2
36 clear cell basal cell carcinoma 10.3 KRT17 KRT7
37 endocervical carcinoma 10.3 KRT7 MUC6
38 cystic basal cell carcinoma 10.3 KRT20 KRT7
39 sertoli-leydig cell tumor 10.3 KRT7 MUC1
40 hepatoid adenocarcinoma 10.3 CDX2 MUC1
41 adenosquamous cell lung carcinoma 10.3 HRAS KRAS
42 polyposis, skin pigmentation, alopecia, and fingernail changes 10.3 CDX2 MUC2
43 microcystic adenoma 10.3 MUC1 MUC6
44 lung acinar adenocarcinoma 10.3 KRT20 KRT7
45 seminal vesicle adenocarcinoma 10.3 KRT20 KRT7
46 transverse colon cancer 10.3 KRT20 KRT7
47 spindle cell sarcoma 10.3 KRT7 MUC1
48 ovarian large-cell neuroendocrine carcinoma 10.3 KRT20 KRT7
49 eyelid neoplasm 10.3 KRT20 KRT7
50 krukenberg carcinoma 10.3 KRT20 KRT7

Graphical network of the top 20 diseases related to Ampulla of Vater Neoplasm:



Diseases related to Ampulla of Vater Neoplasm

Symptoms & Phenotypes for Ampulla of Vater Neoplasm

GenomeRNAi Phenotypes related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

25 (show all 30)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.74 KRT17
2 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.74 KRAS
3 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.74 KRAS
4 Increased shRNA abundance (Z-score > 2) GR00366-A-166 9.74 KRT17
5 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.74 KRAS
6 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.74 KRT17
7 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.74 KRAS
8 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.74 HRAS
9 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.74 KRT17
10 Increased shRNA abundance (Z-score > 2) GR00366-A-196 9.74 KRAS KRT17 HRAS
11 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.74 KRT17
12 Increased shRNA abundance (Z-score > 2) GR00366-A-199 9.74 KRT17
13 Increased shRNA abundance (Z-score > 2) GR00366-A-22 9.74 KRAS
14 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.74 KRAS
15 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.74 KRT17
16 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.74 HRAS
17 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.74 KRT17
18 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.74 KRT17
19 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.74 KRAS KRT17
20 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.74 KRAS
21 Increased shRNA abundance (Z-score > 2) GR00366-A-63 9.74 KRAS
22 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.74 HRAS
23 Increased shRNA abundance (Z-score > 2) GR00366-A-93 9.74 KRAS
24 Decreased viability GR00055-A-2 9.7 HRAS MUC1 KRAS
25 Decreased viability GR00106-A-0 9.7 KRAS
26 Decreased viability GR00221-A-1 9.7 HRAS KRAS
27 Decreased viability GR00221-A-2 9.7 HRAS KRAS
28 Decreased viability GR00221-A-3 9.7 HRAS
29 Decreased viability GR00301-A 9.7 KRAS
30 Decreased viability GR00381-A-1 9.7 KRAS

MGI Mouse Phenotypes related to Ampulla of Vater Neoplasm:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.1 CDX2 HRAS KRAS KRT17 MUC2 SST

Drugs & Therapeutics for Ampulla of Vater Neoplasm

Drugs for Ampulla of Vater Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 56)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2
Pancrelipase Approved, Investigational Phase 3,Phase 1,Early Phase 1,Not Applicable 53608-75-6
3
Cisplatin Approved Phase 3,Phase 1 15663-27-1 2767 441203 84093
4
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
5
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
6
Levoleucovorin Approved, Investigational Phase 3,Phase 1,Phase 2 68538-85-2
7
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
8
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
9 pancreatin Phase 3,Phase 1,Early Phase 1,Not Applicable
10 Antidotes Phase 3,Phase 1,Phase 2
11 Micronutrients Phase 3,Phase 1,Phase 2
12 Protective Agents Phase 3,Phase 1,Phase 2
13 Trace Elements Phase 3,Phase 1,Phase 2
14 Vitamin B Complex Phase 3,Phase 1,Phase 2
15 Vitamins Phase 3,Phase 1,Phase 2
16 Anti-Bacterial Agents Phase 3,Not Applicable
17 Antibiotics, Antitubercular Phase 3,Not Applicable
18 Antiemetics Phase 3
19 Emetics Phase 3
20 Hematinics Phase 3
21 Folate Nutraceutical Phase 3,Phase 1,Phase 2
22 Vitamin B9 Nutraceutical Phase 3,Phase 1,Phase 2
23
Irinotecan Approved, Investigational Phase 1, Phase 2 97682-44-5, 100286-90-6 60838
24
Paclitaxel Approved, Vet_approved Phase 1, Phase 2 33069-62-4 36314
25
Coal tar Approved Phase 1, Phase 2 8007-45-2
26
Docetaxel Approved May 1996, Investigational Phase 2 114977-28-5 148124 9877265
27
Camptothecin Experimental Phase 1, Phase 2 7689-03-4
28
s 1 (combination) Phase 2
29 Anti-Infective Agents Phase 2,Phase 1,Not Applicable
30 Antimetabolites Phase 2,Phase 1
31 Antimetabolites, Antineoplastic Phase 2,Phase 1
32 Antimitotic Agents Phase 2,Phase 1
33 Antiviral Agents Phase 2,Phase 1
34 Immunosuppressive Agents Phase 2,Phase 1
35 Albumin-Bound Paclitaxel Phase 1, Phase 2
36 Antineoplastic Agents, Phytogenic Phase 1, Phase 2
37 Calcium, Dietary Phase 1, Phase 2
38 topoisomerase I inhibitors Phase 1, Phase 2
39 Topoisomerase Inhibitors Phase 1, Phase 2
40 Antibodies Phase 1, Phase 2
41 Immunoglobulins Phase 1, Phase 2
42 Immunotoxins Phase 1, Phase 2
43
Erlotinib Hydrochloride Phase 1 183319-69-9 176871
44 Liver Extracts Phase 1
45 Protein Kinase Inhibitors Phase 1
46
Iodine Approved, Investigational Not Applicable 7553-56-2 807
47
Menthol Approved Early Phase 1 2216-51-5 16666
48
Cefotaxime Approved Not Applicable 63527-52-6 5742673 456256
49
Cefoxitin Approved Not Applicable 35607-66-0 441199
50
Vitamin A Approved, Nutraceutical, Vet_approved Early Phase 1 68-26-8, 11103-57-4 445354

Interventional clinical trials:

(show all 39)

# Name Status NCT ID Phase Drugs
1 Early Enteral Feeding After Pylorus Preserving Pancreatoduodenectomy Unknown status NCT00809081 Phase 3
2 Reduced Pancreatic Fistula Rate Following Pancreaticoduodenectomy: Trial on Pancreaticogastrostomy Versus Pancreaticojejunostomy Completed NCT00830778 Phase 3
3 Active Symptom Control Alone or With mFOLFOX Chemotherapy for Locally Advanced/ Metastatic Biliary Tract Cancers Active, not recruiting NCT01926236 Phase 3 L-folinic acid;5 FU;Oxaliplatin
4 Study of S-1 Oxaliplatin (SOX) for Biliary Tract Cancer (BTC) (Ampullary Adenocarcinoma) Unknown status NCT01180153 Phase 2 S-1 oxaliplatin
5 A Feasibility Phase II Study in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers Completed NCT00660699 Phase 2 Gemcitabine;Docetaxel
6 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
7 Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer Completed NCT02333188 Phase 1, Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
8 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
9 Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer Completed NCT00987766 Phase 1 erlotinib hydrochloride;gemcitabine hydrochloride;oxaliplatin
10 Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers Completed NCT00183846 Phase 1 irinotecan
11 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
12 ABC-08: Phase Ib Trial of Acelarin in Combination With Cisplatin in Locally Advanced/ Metastatic Biliary Tract Cancers Recruiting NCT02351765 Phase 1 Acelarin;Cisplatin
13 Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies Active, not recruiting NCT01643499 Phase 1 oxaliplatin;irinotecan hydrochloride;leucovorin calcium;fluorouracil
14 Radioactive Stents for Treatment of Unresectable Biliary Tract Cancer Unknown status NCT02238613 Not Applicable
15 Small Bowel Endoscopic Evaluation in Familial Adenomatous Polyposis (FAP) Unknown status NCT02656134
16 Endoscopic Papillectomy for Early Ampullary Tumors: Long-term Results of the First Large Multicenter Prospective Study Completed NCT01764503
17 Endoscopic Ultrasound Staging of Periampullary Neoplasms: Retrospective Completed NCT00880633
18 Biliary Cannulation During Endoscopic Retrograde Cholangiopancreatography: Precut Versus Conventional Cannulation Completed NCT02477228
19 Perioperative Cancer Cell Dissemination and Systemic Immune Suppression in Resectable Ductal Pancreatic Adenocarcinoma Completed NCT00495924
20 Loop-tipped Guidewire in Selective Biliary Cannulation Completed NCT02028845
21 Pancreatic Head and Peri-ampullary Cancer Laparoscopic vs Open Surgical Treatment Trial (PLOT) Completed NCT02081131 Not Applicable
22 Comparison Between Fully Covered Metal Stents and Plastic Stents in Preoperative Biliary Drainage Completed NCT01789502 Not Applicable
23 Fatigue and Pancreas and Bile Duct Cancer Study Completed NCT00902759 Early Phase 1
24 Reconstruction Following Pancreaticoduodenectomy: A Randomized Clinical Trial of Pancreaticojejunostomy vs Pancreaticogastomy Completed NCT00841607 Not Applicable
25 Endoscopic Versus Percutaneous Drainage For Hilar Block in Gall Bladder Cancer Completed NCT00409864 Not Applicable
26 Comparison Between Internal and External Preoperative Biliary Drainage in Periampullary Cancers Completed NCT01134276 Not Applicable
27 Trial on the Evaluation of Pylorus-ring in Pancreaticoduodenectomy Completed NCT00639314 Not Applicable
28 Randomized Controlled Trial on Pancreatic Stent Tube in Pancreaticoduodenectomy Completed NCT00628186 Not Applicable
29 Clinical Outcomes of the Endoscopic Resection of Premalignant and Malignant Gastrointestinal Lesions Recruiting NCT01750619
30 Endobiliary RFA for Unresectable Malignant Biliary Strictures Recruiting NCT01844245 Not Applicable
31 Biliary Cancer in Italy: a Study on Cholangiocarcinoma cAUSEs and Risk Factors Recruiting NCT02665494
32 Periampullary Lesions Via ERCP in Assuit University Hospital Recruiting NCT03185390 Not Applicable
33 Enteral Nutrition After Pancreaticoduodenectomy Recruiting NCT03150615 Not Applicable
34 T-EUS for Gastrointestinal Disorders: A Multicenter Registry Recruiting NCT01522573
35 Effectiveness of Prophylactic Antibiotics to Prevent Post Endoscopic Retrograde Cholangio Pancreatography Bacteremia in Biliary Obstruction Patient Recruiting NCT02958059 Not Applicable
36 Interventional Endoscopy Database for Pancreatico-biliary, Gastrointestinal and Esophageal Disorders Recruiting NCT01438385
37 Margin Status After Pancreaticoduodenectomy for Cancer Active, not recruiting NCT03267966 Not Applicable
38 Surgery for Pancreatic Tumors and Collection of Tumor Tissue for Study Terminated NCT00100321
39 Reduced Intra-operative Blood Loss in Pancreaticoduodenectomy for Pancreatic or Peri-ampullary Tumors; Monocentric Trial on Standard Open Versus Minimally Invasive Surgery Withdrawn NCT01712971

Search NIH Clinical Center for Ampulla of Vater Neoplasm

Genetic Tests for Ampulla of Vater Neoplasm

Anatomical Context for Ampulla of Vater Neoplasm

Publications for Ampulla of Vater Neoplasm

Articles related to Ampulla of Vater Neoplasm:

# Title Authors Year
1
Adenosquamous Carcinoma of Ampulla of Vater-a Case Report with Review of Literature. ( 26411563 )
2015
2
Primary adenosquamous carcinoma of ampulla of Vater-A rare case report. ( 24879329 )
2014
3
Prognostic significance of vascular endothelial growth factor expression and microvessel density in carcinoma of ampulla of Vater. ( 16506374 )
2006

Variations for Ampulla of Vater Neoplasm

Expression for Ampulla of Vater Neoplasm

Search GEO for disease gene expression data for Ampulla of Vater Neoplasm.

Pathways for Ampulla of Vater Neoplasm

Pathways related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

(show all 14)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.37 CDX2 HRAS KRAS MUC2
2
Show member pathways
11.93 MUC1 MUC2 MUC6
3 11.75 KRT17 KRT20 KRT7 MUC1
4
Show member pathways
11.66 MUC1 MUC2 MUC6
5
Show member pathways
11.43 HRAS KRAS MUC1 MUC2 MUC6
6
Show member pathways
11.37 MUC1 MUC2 MUC6
7 11.01 HRAS KRAS
8 11 HRAS KRAS
9
Show member pathways
10.97 HRAS KRAS
10
Show member pathways
10.89 HRAS KRAS
11 10.82 HRAS KRAS
12 10.78 HRAS KRAS
13 10.67 HRAS KRAS
14 10.37 HRAS KRAS

GO Terms for Ampulla of Vater Neoplasm

Cellular components related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 intermediate filament GO:0005882 9.13 KRT17 KRT20 KRT7
2 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Ampulla of Vater Neoplasm according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 keratinization GO:0031424 9.61 KRT17 KRT20 KRT7
2 cornification GO:0070268 9.5 KRT17 KRT20 KRT7
3 regulation of long-term neuronal synaptic plasticity GO:0048169 9.4 HRAS KRAS
4 intermediate filament organization GO:0045109 9.37 KRT17 KRT20
5 maintenance of gastrointestinal epithelium GO:0030277 9.26 MUC2 MUC6
6 response to isolation stress GO:0035900 9.16 HRAS KRAS
7 O-glycan processing GO:0016266 9.13 MUC1 MUC2 MUC6
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 HRAS KRAS MUC1 MUC2 MUC6

Sources for Ampulla of Vater Neoplasm

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....